Peptides for Gut Health

01BPC-157small human trial, abstract only

the guide

a 15-amino-acid fragment of a protein first isolated from human gastric juice. its gut case is rat work on ulcers, fistulas, bowel anastomoses and short bowel, and three in four of its PubMed records come from one Zagreb group: 175 of the 233 that mention BPC 157 list Predrag Sikiric as an author (search run 20 October 2026).

evidence: in people, one gut trial, and it was an enema: 53 adults with ulcerative colitis got BPC-157 or placebo rectally for two weeks. the only report of it is a 2005 meeting abstract, and the gap in disease scores between the groups had a confidence interval that crossed zero. FDA's 2026 review looked at BPC-157 specifically as an ulcerative colitis treatment and concluded there is a lack of evidence that it works. no published human study has given it by mouth; an oral tablet trial in Mexico that planned 42 volunteers (NCT02637284) never posted results.

watch for: the enema put no measurable BPC-157 into the blood, so the one human gut result says nothing about any other route. the group's 2011 review calls it 'safe in inflammatory bowel disease clinical trials'; the trials behind that phrase are meeting abstracts. FDA's briefing for its July 2026 advisory committee weighed against adding it to the compounding list.

02KPVanimal and cell only

the guide

the last three amino acids of alpha-MSH, Lys-Pro-Val. its gut logic is a transporter: PepT1 normally carries di- and tripeptides into small-intestine cells, it carries KPV into gut lining and immune cells, and it shows up in inflamed colon but not in normal colon.

evidence: cells and mice only. in human gut and T-cell lines, nanomolar KPV damped NF-kB and MAP kinase signaling, and KPV in drinking water reduced DSS and TNBS colitis in mice (Dalmasso 2008, Emory). a Muenster group saw the same direction in DSS and T-cell transfer colitis, and in mice with a non-working MC1R receptor KPV kept every treated animal alive through DSS colitis, so the effect is at least partly independent of melanocortin signaling (Kannengiesser 2008). FDA has identified no human exposure data for KPV by any route.

watch for: the inflamed-colon targeting comes from a 2001 biopsy study: PepT1 turned up in colon from 10 people with ulcerative colitis or Crohn's disease and in none of 4 normal colons, so the idea applies to inflamed tissue. no dose, blood level or adverse event in a person has been published for any KPV product.

03Larazotidehuman trials

the guide

the tight-junction drug candidate: an eight-amino-acid peptide whose structure comes from a protein secreted by Vibrio cholerae, taken by mouth in trials to stop gluten from opening the seals between gut cells in celiac disease.

evidence: the deepest human gut record here, and a mixed one. in a 2007 inpatient gluten challenge, permeability rose 70% on placebo and not at all on the drug (Paterson 2007). two larger outpatient challenge trials, 86 and 184 patients, could not show a permeability difference, though symptom scores and antibody rises came out lower at some doses (Leffler 2012; Kelly 2013). in 342 adults still symptomatic on a gluten-free diet, the lowest dose met the primary symptom endpoint and the two higher doses did not (Leffler 2015). the phase 3 enrolled 307 and was terminated by its sponsor in July 2022 with no results posted (NCT03569007).

watch for: the dose response in the 342-patient trial ran backwards, which makes its positive arm harder to read. the barrier effect it was built for is the endpoint that failed in outpatients: a meta-analysis of four trials and 626 patients found no permeability difference from placebo (Hoilat 2021). every trial kept people on a gluten-free diet or a measured gluten challenge. adverse events ran close to placebo, with headache and urinary tract infection the most common in the 86-patient trial.

04L-Glutaminesmall human trials

the guide

the one non-peptide: an amino acid sold as a dietary supplement. it is here because it holds the most striking randomized gut result on the page, which makes it the best test of how far one trial can carry a claim.

evidence: 106 adults with diarrhea-predominant IBS that began after a gut infection, all with raised gut permeability, finished 8 weeks of glutamine or placebo: 79.6% on glutamine reached the 50-point symptom drop against 5.8% on placebo, and the lactulose-mannitol ratio normalised on glutamine only (Zhou 2019). a 50-person Tehran trial added glutamine to a low-FODMAP diet and reported more responders than the diet alone (Rastgoo 2021). in active Crohn's disease, a Cochrane review found two small trials, 42 patients, with no remission or permeability benefit (Akobeng 2016).

watch for: placebo responders were 5.8% in that IBS trial against 37.5% pooled across 73 IBS drug trials (Ford 2010), and the authors asked for larger trials themselves. the result covers IBS-D after an infection with a leaky test, not IBS in general. glutamine is not inert everywhere: in a 1,223-patient trial, the ventilated ICU adults with multiorgan failure randomised to glutamine by vein and feeding tube had higher in-hospital and six-month mortality than those who were not (Heyland 2013).

05LL-37small human trials, none in the gut

the guide

the only cathelicidin humans make: an antimicrobial peptide released by neutrophils and made by gut lining cells and colon macrophages. it sits on this bench because the gut already makes it, which is the firmest fact about it.

evidence: the human gut data is about the LL-37 people already make: raised in ulcerative colitis biopsies and unchanged in Crohn's disease in an 89-patient study (Schauber 2006), raised in inflamed mucosa of both in a later Japanese study (Kusaka 2017). mice that cannot make cathelicidin got worse DSS colitis (Koon 2011). the peptide itself has been given to people only on skin ulcers and, in a 4-person MD Anderson study, by injection into melanoma skin lesions (NCT02225366). a 34-person leg-ulcer trial favoured the lowest strength (Gronberg 2014), and the 148-patient phase 2b found no healing difference from placebo across the whole group (Mahlapuu 2021). nobody has given it to a human gut.

watch for: wrapped around the body's own DNA, LL-37 switches on the interferon-making dendritic cells that drive psoriasis (Lande 2007); in lupus it sits inside the DNA immune complexes, and 41% of 38 patients carried antibodies to it (Lande 2011). FDA's compounding entry, current as of 22 April 2026, cites nonclinical findings of harm to male reproduction and says it can be protumorigenic in some tissues.

BPC-157, KPV and LL-37 get sold for the gut next to larazotide and L-glutamine, the two with peer-reviewed human gut trials. larazotide in celiac disease and L-glutamine in IBS show what tested gut evidence looks like, and the three peptides get read against them. no amounts, no schedules. the Peptides for Gut Health bench covers 5 compounds: BPC-157, KPV, Larazotide, L-Glutamine, LL-37, and BodyHackGuide publishes no protocol for any of them.